Studies exhibited that COVID-19 patients who develop serious complications experience a cytokine storm, also known as Cytokine Release Syndrome which led to excessive inflammation, organ failure, and even death, according to the company.
CytoSorb aims to reduce the cytokine storm as well as the deadly inflammatory response by blood purification such that the injury may be mitigated or prevented.
The approval was given by the DCGI from MD-15 for reducing pro-inflammatory cytokine levels in order to control the cytokine storm and benefit COVID-19 patients who are in a critical condition as per the statements.
Biocon’s Executive Chairperson Kiran Mazumdar-Shaw stated that “the CytoSorb is an in-licensed device that reduces cytokine storm in critically ill patients and was introduced by the company in India in 2013. Since then many patients undergoing organ transplant and sepsis treatment have benefitted from it.”
“Weapon against COIVD”
CytoSorb is said to be an important addition to the Indian medical community’s weapons against the deadly coronavirus, Mazumdar-Shaw said.
It can help treat several cases including hemoperfusion, hemodialysis, continuous renal replacement therapy, and extracorporeal membrane oxygenation machines, Biocon said.
In April, the US Food and Drug Administration granted Emergency Use Authorisation of CytoSorb for use in patients with COVID-19 infection, the statement added.
